[Skip to Content]
[Skip to Content Landing]
Views 1,094
Citations 0
News From the Food and Drug Administration
April 3, 2018

Reducing Lung Cancer Progression With Immunotherapy

JAMA. 2018;319(13):1314. doi:10.1001/jama.2018.2928

The FDA has expanded its approval of durvalumab to include treating patients with unresectable stage III non–small cell lung cancer (NSCLC) whose tumors haven’t progressed following chemoradiation.

Marketed as Imfinzi, durvalumab was approved in 2017 for certain patients with locally advanced or metastatic bladder cancer. The drug is a human monoclonal antibody that binds to programmed death ligand 1 and blocks its ability to help tumors evade an immune system attack.